Weight-loss drugs like Ozempic drive $21B sales in 2023

The Conversation April 1, 2024, 08:00 PM UTC

Summary: The rise of weight-loss drugs like Ozempic, originally developed for type 2 diabetes, has generated A$21 billion in sales in 2023. Novo Nordisk's semaglutide, marketed as Ozempic, leads to around 15% weight loss. Mounjaro, a new drug targeting GIP and GLP-1 receptors, has shown 18% weight loss. Clinical trials of Eli Lilly's retatrutide have demonstrated a weight loss of around 24%. These drugs must be injected due to their large peptide molecules. Pfizer and Eli Lilly are developing oral GLP-1 receptor-targeting drugs.

Full article

Article metrics
Significance6.5
Scale8.0
Magnitude7.5
Potential8.5
Novelty7.0
Actionability6.0
Immediacy9.0
Positivity7.0
Credibility9.0

Also covered in:

[6.1]
Ozempic weight-loss drug gaining popularity despite side effects (The Conversation)
[5.3]
Medicare spending on diabetes drugs increased significantly in 2022 (CNN)
[5.0]
Biocon Ltd enters weight loss drug market amid expiring patents (Mint)
[4.0]
New weight-loss drugs may surpass Wegovy's effectiveness (Irish Medical Times)
[3.5]
Ozempic may impact pregnancy despite birth control use (WFLA)
[2.7]
Semaglutides' weight loss benefits may be overestimated (New York Post )